Real-world analysis of cardiovascular adverse events and risk factors after immune checkpoint inhibitor therapy.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, offering significant survival benefits across diverse malignancies. However, growing evidence suggest an increased occurrence of cardiovascular adverse events (CVAEs) following ICI, which remain poorly characterized in large, real-world populations.

Objectives

To quantify the incidence and spectrum of CVAEs following ICI initiation and identify demographic, clinical, and treatment-related risk factors for CVAE development.

Methods

We conducted a retrospective cohort study using electronic health record data from the OneFlorida + Clinical Research Network. Adult cancer patients (≥ 18 years) with cancer who started FDA-approved ICIs between January 1, 2018, and December 31, 2023, were inc

SUBMITTER: Wang Y 

PROVIDER: S-EPMC12625557 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature